A big step for MYC-targeted therapies

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-04-05 DOI:10.1016/j.trecan.2024.03.009

Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher

引用次数: 0

Abstract

The MYC proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by Garralda et al. of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.

查看原文本刊更多论文

向MYC靶向疗法迈出一大步

MYC 原癌基因编码一种主转录调节因子，在人类癌症中经常发生失调。数十年的努力都未能找到 MYC 靶向治疗药物，这仍然被认为是药物开发的圣杯。我们重点介绍 Garralda 等人最近关于 OMO-103 在实体瘤恶性肿瘤患者中的 1 期临床试验的报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.